Ποια είναι η τιμή για ABVC BioPharma, Inc. (ABVC)

Η τιμή για ABVC BioPharma, Inc. (ABVC) είναι $0.9142

Ποια είναι η κεφαλαιοποίηση αγοράς για ABVC BioPharma, Inc. (ABVC)

Η κεφαλαιοποίηση αγοράς για ABVC BioPharma, Inc. (ABVC) είναι $23.77M

ABVC BioPharma, Inc. (ABVC) Κέρδη ανά Μετοχή

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer. ABV-1504 has successfully completed Phase II clinical trials for major depressive disorders. ABV-1505 is progressing through Phase II clinical studies for attention deficit hyperactivity disorder (ADHD). ABV-1703 has concluded its Phase I clinical trials for the treatment of pancreatic cancer. ABV-1702 has also finished Phase I clinical investigations for myelodysplastic syndromes. ABV-1601 is in Phase I/II clinical trials, aimed at alleviating depression in individuals with cancer. ABV-1701 Vitargus is in development to treat conditions such as retinal detachment or vitreous hemorrhage. ABVC BioPharma maintains strategic alliances, including a co-development arrangement with Rgene Corporation, alongside collaborative agreements with BioHopeKing Corporation and BioFirst Corporation. The company's headquarters are located in Fremont, California, and it operates as a subsidiary of YuanGene Corporation.

Έτος	EPS	Αλλαγή
Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Έτος

EPS

Αλλαγή

Δεν υπάρχουν αρκετά δεδομένα για τις παρεχόμενες ημερομηνίες.

Εταιρεία	EPS	Διαφορά EPS	Χώρα
Vertex Pharmaceuticals Incorporated VRTX.US	$17.32	-	US
Argenx SE ARGX.US	$27.74	-	NL
Moderna, Inc. MRNA.US	$-7.98	-	US
CSL Limited CSL.AX	$2.98	-	AU
Lonza Group AG LONN.SW	-	-	CH

Εταιρεία

EPS

Διαφορά EPS

Χώρα